We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...

Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...